Morgan Stanley Plus Therapeutics, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.27 - $0.48 $2 - $3	8 Added 400.0%	10 $0
Q4 2022 Feb 14, 2023	SELL	$0.3 - $0.48 $1 - $1	-4 Reduced 66.67%	2 $0
Q3 2022 Nov 14, 2022	SELL	$0.48 - $1.0 $56,842 - $118,421	-118,421 Reduced 99.99%	6 $0
Q2 2022 Oct 27, 2022	SELL	$0.46 - $1.02 $1,771 - $3,929	-3,852 Reduced 3.15%	118,427 $64,000
Q2 2022 Aug 15, 2022	SELL	$0.46 - $1.02 $1,771 - $3,929	-3,852 Reduced 3.15%	118,427 $64,000

Q1 2022 Oct 27, 2022	BUY	$0.87 - $1.32 $3,351 - $5,084	3,852 Added 3.25%	122,279 $123,000
Q1 2022 May 13, 2022	BUY	$0.87 - $1.32 $103,151 - $156,505	118,565 Added 3192.38%	122,279 $123,000
Q4 2021 Feb 14, 2022	BUY	$1.03 - $1.94 $3,786 - $7,131	3,676 Added 9673.68%	3,714 $4,000
Q3 2021 Nov 15, 2021	BUY	$1.83 - $2.46 $69 - $93	38 New	38 $0

Ticker PSTV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,601,400
Market Cap $51.4M
Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, lep...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.